Key result
Antiplatelet therapy with aspirin and/or clopidogrel in patients with sticky platelet syndrome resulted in a 96.4% freedom from rethrombosis rate at 129 months.
Why the study?
Do antiplatelet drugs reduce platelet hyperaggregability and prevent rethrombosis in patients with sticky platelet syndrome?
Cohort (n=55)
Do antiplatelet drugs reduce platelet hyperaggregability and prevent rethrombosis in patients with sticky platelet syndrome?
Antiplatelet therapy with aspirin and/or clopidogrel effectively reduces platelet hyperreactivity and is associated with a very low rate of rethrombosis in patients with sticky platelet syndrome.
May support antiplatelet therapy in sticky platelet syndrome; leaves open need for randomized confirmation.
INTRODUCTION: The sticky platelet syndrome (SPS) is a common cause of thrombosis. There are no prospective studies concerning treatment. OBJECTIVE: To analyze changes in platelet hyperaggregability of patients with SPS who were given antiplatelet drugs and to assess its association with rethrombosis. METHODS: A total of 55 patients with a history of thrombosis and SPS phenotype were prospectively studied before and after treatment with aspirin and/or clopidogrel. RESULTS: Patients were followed for 1 to 129 months, median 13. Of 55 patients, 40 received aspirin, 13 received aspirin + clopidogrel, and 2 received only clopidogrel. The platelet aggregation response to adenosine diphosphate and epinephrine significantly diminished after treatment, and only 2 patients developed rethrombosis 52 and 129 months after starting therapy, with the freedom from rethrombosis rate of the patients being 96.4% at 129 months. CONCLUSION: Using antiplatelet drugs, the platelet hyperreactivity of patients with the SPS phenotype was reverted; and this translated into a substantial decrease in the rethrombosis rate.
No takes yet. Share an insight, caveat, or question.
Velázquez-Sánchez-de-Cima et al. (2013) conducted a cohort in Sticky platelet syndrome (SPS) and history of thrombosis (n=55). Aspirin and/or clopidogrel vs. Baseline (before treatment) was evaluated on Freedom from rethrombosis. Antiplatelet therapy with aspirin and/or clopidogrel in patients with sticky platelet syndrome resulted in a 96.4% freedom from rethrombosis rate at 129 months.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: